Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Dec 14, 2016Health Canada has approved AFSTYLA, CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.
14 Dec 2016 AFSTYLA is the first and only single-chain recombinant factor VIII for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available In...
-
Dec 9, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Dec 7, 2016
PDF VERSION OF PRESS RELEASE Back to overview of Press Releases
-
Dec 3, 2016Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.
03 Dec 2016 Analysis of clinical trial efficacy results and estimated factor IX levels suggests that patients who maintain factor IX activity levels above 5 and 10 percent have significantly...
-
Dec 2, 2016CSL Behring’s RAPID Extension Study data confirms disease-modifying effect of Respreeza® in patients with AATD.
02 Dec 2016 Global biotherapeutics leader CSL Behring announced today that data from the RAPID Open Label Extension study, conducted in patients with alpha-1 antitrypsin deficiency (AATD),...